ENTPD1 and type 1 diabetes mellitus: While targeted immunosuppression with CD39+ CAR Tregs could be used for auto-immune diseases like T1D, we speculate that our findings could also influence use of CD39– cytotoxic CAR Tregs in other settings, like neuroendocrine cancer targeting.